Company: RDPTF
Filing Date: 2025-09-18
Form Type: 20-F
Source: 0001213900-25-088699
Chunk: 13

Company: Radiopharm Theranostics Ltd
Filing Date: 2025-09-18
Form: 20-F
Item: Item 3
Chunk 13
---
 or quality

We rely on third party supply
and manufacturing partners to manufacture and supply the materials for our research and development and preclinical and clinical study
supplies. We do not own manufacturing facilities or supply sources for such materials.

There can be no assurance
that our supply of research and development, preclinical and clinical development biologics and other materials will not be limited, interrupted
or restricted in certain geographic regions, be of satisfactory quality or continue to be available at acceptable prices. Replacement
of a third-party manufacturer could require significant effort, cost and expertise because there may be a limited number of qualified
replacements.

The manufacturing
process for a drug candidate is subject to FDA and foreign regulatory authority review. Suppliers and manufacturers must meet
applicable manufacturing requirements and undergo rigorous facility and process validation tests required by regulatory authorities
in order to comply with regulatory standards. In the event that any of our suppliers or manufacturers fails to comply with such
requirements or to perform its obligations to us in relation to quality, timing or otherwise, or if our supply of components or
other materials becomes limited or interrupted for other reasons, we may be forced to manufacture the materials ourselves or enter
into an agreement with another third party, which would be costly and delay any future clinical trials.

Further, if any third-party
provider fails to meet its obligations to manufacture our products, or fails to maintain or achieve satisfactory regulatory compliance,
the development of such substances and the commercialization of any therapies, if approved, could be stopped, delayed or made commercially
unviable, less profitable or may result in enforcement actions against us.

Our research and development efforts will be jeopardized if we
are unable to retain key personnel and cultivate key academic and scientific collaborations

Changes in our senior management
can be disruptive to our business and may adversely affect our operations. For example, when we have changes in senior management positions,
we may elect to adopt different business strategies or plans. Any new strategies or plans, if adopted, may not be successful and if any
new strategies or plans do not produce the desired results, our business may suffer.

Moreover, competition among
biotechnology and pharmaceutical companies for qualified employees is intense and as such we may not be able to attract and retain personnel
critical to our success. Our success depends on our continued ability to attract, retain and motivate highly qualified management, clinical
and scientific personnel, manufacturing personnel, sales and marketing personnel and on our ability to develop and maintain important
relationships with clinicians, scientists and leading academic and health institutions